Skip to main content

Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation.

McGlasson DL, Kaczor DA, Krasuski RA, Campbell CL, Kostur MR, Adinaro JT

Publication: Blood Coagul Fibrinolysis (2005) • Vol 16 • Page 173-6PMID: 15795534View on PubMed

Purpose

The purpose of this paper was to determine the effects of different specimen collection methods on anti-activated factor X (anti-FXa) assay and activated partial thromboplastin time (aPTT) results for patients receiving unfractionated heparin (UFH) and low molecular weight heparin (LMWH) therapy.

Conclusion

Specimens from UFH patients collected into 3.8% sodium citrate with ratio of 6:1 (blood: anticoagulant) showed a statistically significant increase in aPTT. No other combinations of anticoagulant and blood/anticoagulant ratio resulted in statistically significant differences in aPTT for patients receiving UFH or LMWH therapy. Importantly, neither blood to anticoagulant ratio nor type of anticoagulant affected anti-FXa assay results for either heparin therapy suggesting this assay is better suited for monitoring heparin patients.

Studies (1)

Purpose

The purpose of this study was to determine if the use of different anticoagulants or the ratio of blood to anticoagulant during specimen collection affects anti-FXa assay results or aPTT for patients receiving UFH and LMWH therapy. Plasma specimens were stored at -70 degrees C prior to analysis.

Summary of Findings

Specimens from UFH patients collected into 3.8% sodium citrate with ratio of 6:1 (blood: anticoagulant) showed a statistically significant increase in aPTT (p=0.06) with an average time of 127.2 s versus 105.4 s when specimens were collected using standard methods (3.2% sodium citrate and a 9:1 blood to anticoagulant ratio). However, some UFH specimens had aPTT times over 300 s which could have skewed the mean. No other combinations of anticoagulant and blood/anticoagulant ratio resulted in statistically significant differences in aPTT for patients receiving UFH or LMWH therapy. There were several aPTT times which did not correlate with the amount of heparin, indicating an effect of other variables besides heparin on aPTT. Importantly, neither blood to anticoagulant ratio nor type of anticoagulant affected anti-FXa assay results for either heparin therapy suggesting this assay is better suited for monitoring heparin patients.

  • Biospecimens

    FluidBlood
    FluidPlasma
  • Preservation Types

    Frozen
  • Diagnoses

    Coronary Artery Disease
    Other diagnoses
  • Platforms

    ProteinHematology/ auto analyzer
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Antiphospholipid antibody syndrome
    Deep vein thrombosis
    Other diagnoses
    Recurrent spontaneous abortion
    PreaquisitionOther drugs
    Low molecular weight heparin
    Unfractionated heparin
    Biospecimen AcquisitionAnticoagulant
    Citrate-theophylline-adenosine-dipyridamole
    Sodium citrate
    Biospecimen Aliquots and ComponentsAliquot size/volume
    6:1 blood to anticoagulant ratio
    9:1 blood to anticoagulant ratio